Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
24
08
2020
accepted:
10
05
2021
revised:
23
04
2021
pubmed:
29
5
2021
medline:
23
6
2022
entrez:
28
5
2021
Statut:
ppublish
Résumé
Malignant sweat gland tumours are rare, with the most common form being Eccrine porocarcinoma (EP). To investigate the mutational landscape of EP, we performed whole-exome sequencing (WES) on 14 formalin-fixed paraffin-embedded samples of matched primary EP and healthy surrounding tissue. Mutational profiling revealed a high overall median mutation rate. This was attributed to signatures of mutational processes related to ultraviolet (UV) exposure, APOBEC enzyme dysregulation, and defective homologous double-strand break repair. All of these processes cause genomic instability and are implicated in carcinogenesis. Recurrent driving somatic alterations were detected in the EP candidate drivers TP53, FAT2, CACNA1S, and KMT2D. The analyses also identified copy number alterations and recurrent gains and losses in several chromosomal regions including that containing BRCA2, as well as deleterious alterations in multiple HRR components. In accordance with this reduced or even a complete loss of BRCA2 protein expression was detected in 50% of the investigated EP tumours. Our results implicate crucial oncogenic driver pathways and suggest that defective homologous double-strand break repair and the p53 pathway are involved in EP aetiology. Targeting of the p53 axis and PARP inhibition, and/or immunotherapy may represent promising treatment strategies.
Identifiants
pubmed: 34045664
doi: 10.1038/s41417-021-00347-z
pii: 10.1038/s41417-021-00347-z
pmc: PMC9209330
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
697-708Informations de copyright
© 2021. The Author(s).
Références
Rütten A. [Eccrine sweat gland carcinoma of the skin]. Pathologe. 2002;23:79–88.
doi: 10.1007/s00292-001-0516-y
Rütten A, Requena L Schweißdrüsenkarzinome der Haut. Der Hautarzt. 2008;151–60.
De Giorgi V, Salvati L, Barchielli A, Caldarella A, Gori A, Scarfì F, et al. The burden of cutaneous adnexal carcinomas and the risk of associated squamous cell carcinoma: a population-based study. Br J Dermatol. 2019;565–73.
Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine Porocarcinoma. Dermatologic Surg. 2018;180:1247–61.
Huet P, Dandurand M, Pignodel C, Guillot B. Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol. 1996;35:860–4.
Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine Porocarcinoma: new insights and a systematic review of the literature. Dermatol Surg. 2018;1247–61.
Xu YG, Aylward J, Longley BJ, Hinshaw MA, Snow SN eccrine porocarcinoma treated by mohs micrographic surgery. Dermatologic Surg. 2015;41:685–92.
Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25:710–20.
Thibodeau ML, Bonakdar M, Zhao E, Mungall KL, Reisle C, Zhang W, et al. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. npj Precis Oncol. 2018;8:1–6.
Bosic M, Kirchner M, Brasanac D, Leichsenring J, Lier A, Volckmar A-L, et al. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. Pathology. 2018;50:327–32.
Harms PW, Hovelson DH, Cani AK, Omata K, Haller MJ, Wang MML, et al. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol. 2016;51:25–31.
Takata M, Hashimoto K, Mehregan P, Lee MW, Yamamoto A, Mohri S, et al. Genetic changes in sweat gland carcinomas. J Cutan Pathol. 2000;51:30–5.
Reisinger E, Genthner L, Kerssemakers J, Kensche P, Borufka S, Jugold A, et al. OTP: an automatized system for managing and processing NGS data. J Biotechnol. 2017;261:53–62.
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2013;491:56–65.
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754–60.
doi: 10.1093/bioinformatics/btp324
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078–9.
doi: 10.1093/bioinformatics/btp352
Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, Prins P. Sambamba: fast processing of NGS alignment formats. Bioinformatics 2015;31:2032–4.
doi: 10.1093/bioinformatics/btv098
Jones DTW, Jäger N, Kool M, Zichner T, Hutter B, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012;488:100–5.
doi: 10.1038/nature11284
Jones DTW, Hutter B, Jäger N, Korshunov N, Kool M, Warnatz HJ, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45:927–32.
doi: 10.1038/ng.2682
ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57–74.
doi: 10.1038/nature11247
Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz GMJ. Integrative genomics viewer. Nat Biotechnol. 2011;29:24–6.
doi: 10.1038/nbt.1754
Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 2016;32:2847–9.
doi: 10.1093/bioinformatics/btw313
Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA Sequencing. PLoS Comput Biol. 2016;12:1–18.
doi: 10.1371/journal.pcbi.1004873
Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.
doi: 10.1186/gb-2011-12-4-r41
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415–21.
doi: 10.1038/nature12477
Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 2018;555:371–6.
doi: 10.1038/nature25795
Sekine Shigeki, Kiyono Tohru, Ryo Eijitsu, Ogawa Reiko, Wakai Susumu, Ichikawa Hitoshi, et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019;129:3827–32.
doi: 10.1172/JCI126185
Wagner AH, Walsh B, Mayfield G, Tamborero D, Sonkin D, Krysiak K, et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet. 2020;52:448–57.
doi: 10.1038/s41588-020-0603-8
Carrasco-Ramiro F, Peiró-Pastor R, Aguado B. Human genomics projects and precision medicine. Gene Ther. 2017;24:551–61.
Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol. 2018;36:46–60.
doi: 10.1038/nbt.4017
Robbe P, Popitsch N, Knight SJL, Antoniou P, Becq J, He M, et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. Genet Med. 2018;20:1196–205.
doi: 10.1038/gim.2017.241
Wilkins A, Chauhan R, Rust A, Pearson A, Daley F, Manodoro F, et al. FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. Breast Cancer Res Treat. 2018;170:573–81.
doi: 10.1007/s10549-018-4798-7
Dahle J, Kvam E. Induction of delayed mutations and chromosomal instability in fibroblasts after UVA-, UVB-, and X-radiation. Cancer Res. 2003;63:1464–9.
pubmed: 12670891
Talluri S, Samur MK, Buon L, Megan SA, Nanjappa P, Prabhala R, et al. Dysregulated Aid/Apobec family proteins promote genomic instability in multiple myeloma. Blood 2016;128:803–803.
doi: 10.1182/blood.V128.22.803.803
Zámborszky J, Szikriszt B, Gervai JZ, Pipek O, Póti, Krzystanek M, et al. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene 2017;36:746–55.
doi: 10.1038/onc.2016.243
Campbell PJ, Getz G, Korbel JO, Stuart JM, Jennings JL, Stein LD, et al. Pan-cancer analysis of whole genomes. Nature 2020;578:82–93.
doi: 10.1038/s41586-020-1969-6
Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature 2020;578:94–101.
doi: 10.1038/s41586-020-1943-3
Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89–102.
Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020;133:jcs237453.
doi: 10.1242/jcs.237453
Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011;8:25–37.
Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–57.
Taha Z, Janse van Rensburg HJ, Yang X. The hippo pathway: Immunity and cancer. Cancers 2018;10:94.
doi: 10.3390/cancers10040094
Holden JK, Cunningham CN. Targeting the hippo pathway and cancer through the TEAD family of transcription factors. Cancers. 2018;10:81
Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015;15:334–46.
Ke T, Gomez CR, Mateus HE, Castano JA, Wang QK. Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a South American family. J Hum Genet. 2009;54:660–4.
doi: 10.1038/jhg.2009.92
Jen JC, Ashizawa T, Griggs RC, Waters MF. Rare neurological channelopathies-networks to study patients, pathogenesis and treatment. Nat Rev Neurol. 2016;12:195–203.
Phan NN, Wang CY, Chen CF, Sun Z, Lai MD, Lin YC. Voltage-gated calcium channels: novel targets for cancer therapy. Oncol Lett. 2017;14:2059–74.
Chen M, Rothman N, Ye Y, Gu J, Scheet PA, Huang M, et al. Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. Genes Cancer. 2016;7:229.
Cai C, Cooper GF, Lu KN, Ma X, Xu S, Zhao Z, et al. Systematic discovery of the functional impact of somatic genome alterations in individual tumors through tumor-specific causal inference. PLoS Comput Biol. 2019;15:e1007088.
doi: 10.1371/journal.pcbi.1007088
Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, et al. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single Circulating Tumor Cells. PLoS ONE. 2014;9:e101777.
Ziogas DE, Spiliotis J, Lykoudis EG, Zografos GC, Roukos DH. Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy. Future Oncol. 2017;13:113–6.
doi: 10.2217/fon-2016-0307
Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578:112–21.
Cortés-Ciriano I, Lee JJK, Xi R, Jain D, Jung YL, Yang L, et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52:331–41.
Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:1–30.
Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: The roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7:a016600.
Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20:698–714.
Hechtman JF, Rana S, Middha S, Stadler ZK, Latham A, Benayed R, et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod Pathol. 2019;33:871–9.
Lin A, Yao J, Zhuang L, Wang D, Han J, Lam EWF, et al. The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress. Oncogene. 2014;33:3183–94.
Méndez-Lucas A, Lin W, Driscoll PC, Legrave N, Novellasdemunt L, Xie C, et al. Identifying strategies to target the metabolic flexibility of tumours. Nat Metab. 2020;2:335–50.
Williams AB, Schumacher B. p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med. 2016;6:a026070.
Sridharan R, Antonina A, Trevor J, Rutherford ARF. Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2. Proc Natl Acad Sci. 2010;107:8587–92.
Sarubi HC, Pereira NB, Gomes CC, Gomez RS, Carmo ACM, Melo FM, et al. Molecular and immunohistochemical analyses of uveal melanoma patient cohort. Melanoma Res. 2019;29:248–53.
doi: 10.1097/CMR.0000000000000523
Adams DJ, Bishop DTR-EC. Melanoma predisposition-A limited role for germline BRCA1 and BRCA2 variants. Pigment Cell Melanoma Res. 2020;33:6–7.
doi: 10.1111/pcmr.12833
Gutermuth J, Audring H, Voit C, Trefzer UHN. Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Venereol. 2004;18:477–9.
doi: 10.1111/j.1468-3083.2004.00949.x
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–8.
Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20:404–16.
doi: 10.1038/s41576-019-0114-6
Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997–1014.
Jung YS, Park J Il. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020;52:183–91.
Sakamoto Y, Sereewattanawoot S, Suzuki A. A new era of long-read sequencing for cancer genomics. J Hum Genet. 2020;65:3–10.
doi: 10.1038/s10038-019-0658-5
Erwin L, van Dijk, Yan J, Delphine Naquin CT. The third revolution in sequencing technology, trends in genetics. Trends Genet. 2018;34:666–81.